Application of nanotechnology in drug delivery systems for respiratory diseases (Review)

Mol Med Rep. 2021 May;23(5):325. doi: 10.3892/mmr.2021.11964. Epub 2021 Mar 24.

Abstract

Respiratory disease is a common disease with a high incidence worldwide, which is a serious threat to human health, and is considered a societal and economic burden. The application of nanotechnology in drug delivery systems has created new treatments for respiratory diseases. Within this context, the present review systematically introduced the physicochemical properties of nanoparticles (NPs); reviewed the current research status of different nanocarriers in the treatment of respiratory diseases, including liposomes, solid lipid nanocarriers, polymeric nanocarriers, dendrimers, inorganic nanocarriers and protein nanocarriers; and discussed the main advantages and limitations of therapeutic nanomedicine in this field. The application of nanotechnology overcomes drug inherent deficiencies to a certain extent, and provides unlimited potential for the development of drugs to treat respiratory diseases. However, most of the related research work is in the preclinical experimental stage and safety assessment is still a challenging task. Future studies are needed to focus on the performance modification, molecular mechanism and potential toxicity of therapeutic nanomedicine.

Keywords: nanoparticle; drug delivery systems; toxicity; inhaled nanoparticles; respiratory disease.

Publication types

  • Review

MeSH terms

  • Drug Carriers / chemistry
  • Drug Carriers / therapeutic use
  • Drug Delivery Systems*
  • Humans
  • Liposomes / chemistry
  • Liposomes / therapeutic use
  • Lung Diseases / drug therapy*
  • Lung Diseases / pathology
  • Nanomedicine / trends
  • Nanoparticles / chemistry
  • Nanoparticles / therapeutic use*
  • Nanotechnology / trends*

Substances

  • Drug Carriers
  • Liposomes